Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide.
+ 1 more risk
Imperfect balance sheet and overvalued.
Share Price & News
How has Microbix Biosystems's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2M4's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2M4 exceeded the German Biotechs industry which returned -13.2% over the past year.
Return vs Market: 2M4 exceeded the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Microbix Biosystems's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Microbix Biosystems undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2M4's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 2M4's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 2M4 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 2M4 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2M4's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2M4 is good value based on its PB Ratio (2.6x) compared to the DE Biotechs industry average (3.3x).
How is Microbix Biosystems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Microbix Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of 2M4’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Microbix Biosystems competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Microbix Biosystems performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2M4 is currently unprofitable.
Growing Profit Margin: 2M4 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2M4 is unprofitable, and losses have increased over the past 5 years at a rate of -52.5% per year.
Accelerating Growth: Unable to compare 2M4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2M4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: 2M4 has a negative Return on Equity (-4.35%), as it is currently unprofitable.
How is Microbix Biosystems's financial position?
Financial Position Analysis
Short Term Liabilities: 2M4's short term assets (CA$6.2M) exceed its short term liabilities (CA$4.9M).
Long Term Liabilities: 2M4's short term assets (CA$6.2M) exceed its long term liabilities (CA$4.9M).
Debt to Equity History and Analysis
Debt Level: 2M4's debt to equity ratio (66.9%) is considered high.
Reducing Debt: 2M4's debt to equity ratio has increased from 61.2% to 66.9% over the past 5 years.
Inventory Level: 2M4 has a high level of physical assets or inventory.
Debt Coverage by Assets: 2M4's debt is not covered by short term assets (assets are 0.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2M4 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 2M4 has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.9% each year.
What is Microbix Biosystems's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2M4's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2M4's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2M4's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2M4's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2M4's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Cameron Groome serves as an Independent Director at iFabric Corp. since March 30, 2020. Mr. Groome has been the Chief Executive Officer and President of Microbix Biosystems Inc. since July 24, 2017. Mr ...
CEO Compensation Analysis
Compensation vs Market: Cameron's total compensation ($USD220.99K) is below average for companies of similar size in the German market ($USD434.26K).
Compensation vs Earnings: Cameron's compensation has increased whilst the company is unprofitable.
|Founder & Executive Chairman||7.42yrs||CA$214.15k||5% CA$847.3k|
|Chief Financial Officer||3.42yrs||CA$232.03k||0.11% CA$19.5k|
|Senior Vice President of Scientific Affairs||12.42yrs||CA$174.68k||0.12% CA$20.5k|
|Senior Vice President of Sales||7.42yrs||CA$216.97k||0.35% CA$59.2k|
|Chief Operating Officer||1yr||no data||0.24% CA$40.5k|
|Compliance Officer||no data||no data||no data|
Experienced Management: 2M4's management team is considered experienced (3.4 years average tenure).
|Founder & Executive Chairman||7.42yrs||CA$214.15k||5% CA$847.3k|
|Independent Director||17.5yrs||no data||0.51% CA$85.6k|
|Independent Director||17.17yrs||no data||6.6% CA$1.1m|
|Independent Director||11.17yrs||no data||0.37% CA$62.4k|
|Independent Director||14.33yrs||no data||1.62% CA$275.3k|
|Independent Director||13.17yrs||no data||0.046% CA$7.8k|
Experienced Board: 2M4's board of directors are seasoned and experienced ( 13.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 2M4 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Microbix Biosystems Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Microbix Biosystems Inc.
- Ticker: 2M4
- Exchange: DB
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$26.099m
- Listing Market Cap: CA$16.957m
- Shares outstanding: 108.75m
- Website: https://microbix.com
Number of Employees
- Microbix Biosystems Inc.
- 265 Watline Avenue
- L4Z 1P3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MBX||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Oct 1992|
|MBXB.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Oct 1992|
|2M4||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Oct 1992|
Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 00:14|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.